New Drug Development

 

New Drug Approval

1 Marzulene S Combination Granules Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent
(1968:Japan, 1990:China, 2000:India)
Marzulene Combination Tablets 1.0ES (Dosage form addition, 2003:Japan)
Marzulene Combination Tablets 0.5ES (Dosage form addition, 2008:Japan)
Marzulene Combination Tablets 0.375ES (Dosage form addition, 2009:Japan)
2 AZULOXA Granules 2.5% Gastric ulcer therapeutic agent
(2001:Japan, 2004:Korea)
AZULOXA Tablets 15mg (Dosage form addition, 2011:Japan)
3 Suglat Tablets 25mg/50mg
(Ipragliflozin (ASP1941) )
Diabetes therapeutic agent/Selective SGLT2 Inhibitor
(Type 2 Diabetes, 2014:Japan, 2015:Korea, 2019:Russia, Joint development with Astellas Pharma Inc.)
(Type 1 Diabetes, 2018:Japan, Joint development with Astellas Pharma Inc.)
4 SUJANU Combination Tablets
(Ipragliflozin/Sitagliptin (MK-0431J) )
Type 2 Diabetes therapeutic agent/Selective DPP-4 inhibitor/Selective SGLT2 Inhibitor
(2018:Japan, Joint development with Astellas Pharma Inc and MSD.)
5 XOSPATA Tablets 40mg
(giliteritinib (ASP2215) )
Antineoplastic drug/FLT3 Mutation
(2018:Japan/US, 2019:Europe/Canada, 2020:Taiwan/Korea/Brazil/Australia, 2021:China/Singapore, Joint development with Astellas Pharma Inc.)
 
八重枝垂桜

 

 

R&D Pipeline(2020.8)

1 ASP2215 (giliteritinib)
①Development stage:Global/Phase Ⅲ
②Target:Acute myeloid leukemia
③Development:Astellas
2 S-556971(KT6-971) ①Development stage:Japan/Phase Ⅱ, Europe/Phase I
②Target:Dyslipidemia
③Development:Kotobuki
3 KT7-533:α-C-Galactosyl Ceramide (Phase I in preparation:Derivation ending)

 

ビデオ会議

 

中圧液体クロマトグラフィー

medium pressure liquid chromatography